Oracle plans $55.7B capex for fiscal 2026, then warns it needs $40B funding in 2027
Q4 revenue grew 21%, but investors are focused on Oracle's $70B net capex outlook and how it pays for it.

Oracle CFO Hilary Maxson said the company will support its capital investments program by raising around $40 billion in debt and equity in fiscal 2027, including a $20 billion equity issuance already announced. Despite Q4 sales rising 21% to $19.2 billion, Oracle's share price fell as markets weighed the increased capex and still-negative free cash flow.
Oracle ended its quarter with revenue growth and a big AI infrastructure message, then immediately handed investors a capex math problem. For the quarter ended May 31, Q4 sales climbed 21% year-on-year to $19.2 billion. But the stock fell anyway, because Wall Street fixated on Oracle’s rising capital spending plans and the question everyone has to answer when AI builds get expensive: how exactly does it fund them?
The funding answer is where things got uncomfortable. CFO Hilary Maxson said Oracle plans to raise around $40 billion in debt and equity in fiscal 2027, and that this includes a $20 billion equity issuance already announced. At the same time, she said Oracle does not anticipate raising additional debt funding in calendar year 2026. The underlying capex ramp is big enough that investors are not just asking whether Oracle will spend, but whether it can spend fast without stressing its balance sheet or free cash flow.
To see the scale, start with the capex figures. Oracle’s capital expenditures for fiscal 2026 reached $55.7 billion, up from $21.2 billion a year earlier. That is an enormous jump in a short period, and it aligns with what Oracle is trying to do in AI datacenters: build capacity to match demand for cloud workloads.
Maxson also put a more detailed net-cash picture on the table, and it is the kind of detail that can move markets even if the headline revenue story looks healthy. She said Oracle expects an expected net cash outlay for capital expenditures of around $70 billion in fiscal 2027. Crucially, she added that this includes customer prepayments and timing impacts expected at around $20 billion to $25 billion, so reported capex will be higher by this amount. In other words, Oracle is telling investors to separate the headline spending from the cash timing reality, but it still expects heavy investment.
Oracle’s case for the investment is also tied to how much contracted revenue is already in the pipeline, even if it is not recognized yet. The company declared $455 billion remaining performance obligations (RPOs), which it described as contracted revenue not yet recognized. The figure was reportedly more than 300% higher than a year earlier. The source notes that this reportedly includes $300 billion for OpenAI alone, reflecting how the AI model provider side of the market is pushing demand for compute capacity and operational scale.
CEO Clay Magouyrk tried to calm one common investor fear: that capex is exploding because components suddenly got more expensive. He said any increase in capex was not due to component prices, and he pointed instead to timing. He also framed his role as finding ways to accelerate capex spending so Oracle can ramp revenue, which is a classic “build now, monetize later” AI infrastructure tradeoff. Still, the company acknowledged the broader pricing environment, saying memory prices have gone up, and also noting SSD and hard drive prices. At the same time, Oracle said it locked prices “across the spectrum,” including space and power costs, energy costs, people costs, and component costs.
Operationally, Oracle continues to add capacity. The company added around 400 MW in Q4, described as similar to the last two quarters, and it expects to add nearly 1 GW of capacity in fiscal Q1 2027. That cadence matters because investors are not only evaluating the total dollars, they are evaluating execution speed and conversion of capacity into recognized revenue.
Even with all of that, there is a second-order pressure point. One analyst told Reuters that there is real demand for cloud infrastructure, but that the funding question is “getting harder, not easier,” especially with capex coming in well above estimates while free cash flow remains negative. For decision-makers, that is the real tension. If free cash flow stays negative while capex stays elevated, boards and CFOs often face a squeeze: balance-sheet management, dilution risk, or the need to prove faster ROI to justify continued borrowing or equity issuance. Oracle’s plan to raise about $40 billion in fiscal 2027, plus an already announced $20 billion equity issuance, puts a spotlight on how much patience investors will grant during the buildout.
Finally, Oracle is also extending its enterprise footprint alongside the infrastructure play. With its latest financial figures, it announced a deal for a Fusion HCM system with the US Office of Personnel Management. That matters because it suggests Oracle is not limiting itself to hyperscale compute and AI workloads; it is also tying its broader enterprise software and services business into a larger customer base.
For peers, this is the template to watch. Oracle is betting that AI datacenter capacity, backed by large RPO commitments and customer prepayments, will translate into ramping revenue. But the market is forcing an additional question into the room: not whether Oracle can build, but whether it can build fast enough, funded cheaply enough, and timed well enough that the equity and debt markets keep lending it the runway.
This story's Key Insights and Take-aways are locked.
Create a free account to unlock Executive Actions for one credit.
Register to UnlockAlways free for Executives Club members. Join the Club
More in Business

SpaceX IPO: Wedbush calls a Tesla merger “holy grail,” Morningstar pegs $63 fair value
Trading starts June 12 at $135, but analysts are split over a $72-per-share “option premium” on orbital AI dreams.

Microsoft SkillOpt upgrades AI agent skills without changing model weights
Open-source framework turns markdown skill files into optimizable objects, boosting accuracy while keeping frozen model parameters untouched.

Britain’s regulator greenlights Novo Nordisk’s weight-loss pill on Thursday, needle-free win
Approval by Britain’s medicines regulator adds a new oral option and strengthens Novo Nordisk’s early lead versus Eli Lilly.
